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Summary Hepatitis A virus (HAV) and hepatitis B virus (HBV) are vaccine-preventable. Current
recommendations advocate vaccination of non-immune adults at risk of exposure, including
travelers to HAV or HBV endemic areas, individuals with high risk of contracting a sexually
transmitted infection, and some correctional facility inmates. We review the use of an accel-
erated schedule to administer the combination hepatitis A and hepatitis B vaccine (Twinrix1).
Administering three doses over three weeks and a fourth at 12 months provides rapid initial
protection of most individuals for whom the standard 6-month vaccination schedule would not be
suitable, including last-minute travelers and short-term correctional facility inmates. Further-
more, we consider the role of a universal vaccination strategy in preventing the spread of HAVand
HBV.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.Introduction: overview of hepatitis A and
hepatitis B diseases
Viral hepatitis is a severe and important global disease.
Several morphologically and antigenically different viruses
can cause hepatitis, but in the Western world most cases are
associated with either the hepatitis A or hepatitis B viruses* Corresponding author. Tel.: +1 416 340 3671; fax: +1 416 595 5826.
E-mail address: jay.keystone@utoronto.ca (J.S. Keystone).
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doi:10.1016/j.ijid.2007.04.012(HAV and HBV, respectively). HAV is a picornavirus, an ico-
sahedral, non-enveloped virus containing positive, single-
stranded RNA.1 HAV replicates in the liver and is excreted
in the stool, surviving in the environment for several weeks.2
It has an approximate incubation period of 28 days (range 15—
50 days), during which viral shedding can occur even though
symptoms may not be apparent. As a result, infected indi-
viduals may not know they are contagious and can unwittingly
spread the infection. HBV is a major carcinogen. It is a
hepadnavirus, a spherical, enveloped virus with a partially
double-stranded, circular DNA genome.1 HBV has a longPublished by Elsevier Ltd. All rights reserved.
4 J.S. Keystone, J.H. Hersheyincubation period of, on average, 90 days (range 60—150
days), but again, infected individuals are highly contagious
soon after exposure and well before they develop signs of
illness. The highest titers of HBVare found in blood and serous
fluids, with lower levels in semen and saliva.
The acute clinical symptoms of viral hepatitis are similar,
regardless of etiologic agent, and may include fever,
malaise, fatigue, anorexia, nausea, abdominal discomfort,
dark urine, and jaundice.2,3 The clinical severity of hepa-
titis A and hepatitis B is age-dependent, leading to more
severe symptoms in adults, but generally being asympto-
matic, yet still highly transmissible in young children. Chil-
dren can be an important reservoir of infection for hepatitis
A. Acute hepatitis A and hepatitis B can only be differen-
tiated on the basis of laboratory tests for specific antibo-
dies.2,3 Chronic carriers of HBVor those with acute infection
can be identified by the HBV surface antigen (HBsAg), which
is not itself infectious, but its presence in the blood indi-
cates that the whole virus is present and the individual is
contagious.3
There are no specific treatments for acute hepatitis A or
hepatitis B. Instead, patients are given supportive therapy
aimed at relieving the symptoms. Passive immunoglobulin
therapy can be administered to prevent acute HAV infection,
but it is most effective (>85%) when administered intramus-
cularly within two weeks after exposure.2 Active immuniza-
tion with the hepatitis A vaccine has been shown to be
approximately 80% effective in preventing secondary HAV
infection in subjects exposed to HAV through household
contact.4 Passive immunoglobulin therapy can also be admi-
nistered to prevent hepatitis B infection from developing and
is used most often for the prevention of perinatal mother-to-
child transmission.3 Immunoglobulin therapy and hepatitis B
vaccination administered together, within 24 hours of birth,
is 85—95% effective in preventing both acute and chronic
infection.3 Interferon may also be used to treat chronic HBV
infection and is successful in 25—50% of cases.3 HAV infection
usually resolves completely, leaving the individual protected
against further episodes of hepatitis A.5 In contrast, approxi-
mately 10% of all acute HBV infections progress to chronic
infection, and such individuals develop chronic liver compli-
cations in later years.3 The risk of chronic HBV infection
decreases with advancing age. Up to 90% of infants with
perinatally acquired HBV will develop chronic infection, and
approximately 5% of adults who acquire HBV will develop
chronic infection.3
Consequences of hepatitis A and hepatitis B
diseases
Although most infected people make a full recovery, with
estimatedmortality rates of only 0.2—0.3%,2,5 hepatitis A can
be associated with significant morbidity. After the preclinical
phase of infection, there is a prodromal period that can last
more than a week. Patients do not have jaundice at this stage
but develop the acute, non-specific symptoms previously
described. Once jaundice develops, fever and viremia start
to resolve, although the patient’s stools are still highly
infectious for another one to two weeks. Up to one-fifth of
patients may relapse during the convalescent phase, but the
infection does not usually persist beyond 12 months.5Disease severity increases with age, meaning symptoms
last longer in older people and the patient is more likely to be
absent from work and be hospitalized. More importantly, the
case fatality ratio of reported hepatitis A cases in the USA
reaches 1.8% over 50 years of age.6 Consequently, the eco-
nomic burden to society, in terms of treatment and employ-
ment costs, is also greater. The estimated annual cost of
hepatitis A to the US economy was more than $480 million in
1997, which was based on 63 363 symptomatic HAV infec-
tions.7 This study estimated that there were 829 000 working
days lost, a total of 8403 hospital admissions, and mean
treatment costs for each hospitalized patient of US $6914.
Mean treatment cost for each non-hospitalized patient was
US $740.7
The incidence of hepatitis A has been decreasing over the
last decade, most likely because of the introduction of
hepatitis A immunization programs in selected states and
communities. However, recent data from the Centers for
Disease Control and Prevention (CDC) indicate that the num-
ber of confirmed cases in the USA during 2004 was 5683, and
there were 14 hepatitis A-related deaths.8
HBV can have serious clinical consequences and it is
associated with long-term complications such as chronic
hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).
Most people with HBV recover completely, but approximately
10% of acute cases develop into chronic carriage.3,9 Globally,
there are estimated to be 450 million chronic carriers of
HBV.10 Chronic hepatitis B is most often asymptomatic but
leads to the gradual destruction of liver tissue. Liver cirrhosis
occurs in asmany as 20% of chronic HBV carriers, and is itself a
risk factor for HCC. Once HCC is clinically apparent, it is
usually fatal, with a median survival of <3 months.11 HBV
persistence is much more likely for a younger patient at first
exposure; in endemic areas, 70—90% of infected infants
become chronic carriers of the virus.9 In 2004, there were
6212 reported cases of hepatitis B in the USA, including 13
deaths.8 Hepatitis B is among the ten leading causes of death
in men worldwide11 and is the most common known cause of
chronic viremia.3 HBV is the cause of up to 80% of HCC and is
second only to tobacco among known human carcinogens.11
Individuals with existing liver disease are at particular risk
of developing fulminant hepatitis if they contract viral hepa-
titis. This is a complication of both HAV and HBV infection, in
which severe liver disease develops rapidly and is often
fatal.9 Fulminant hepatitis A causes approximately 100
deaths per year in the USA. The overall case fatality rate
is approximately 0.3%, rising to 2% in persons 40 years of
age.2 Fulminant hepatitis B occurs in about 1—2% of acutely
infected persons and causes 200—300 deaths per year in the
USA.3Epidemiology
HAV is transmitted by the fecal—oral route by ingestion of
contaminated food or water (one very large recent outbreak
in a Pennsylvania restaurant was traced to contaminated
green onions12), or by close personal contact with infected
individuals.2 HAV-infected persons are most contagious 1—2
weeks before the onset of illness, but viral shedding
decreases significantly 7—10 days after the patient becomes
symptomatic. HAV is highly endemic in Mexico, Central and
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Figure 1 Geographic prevalence of (A) hepatitis A and (B) hepatitis B.15South America, Greenland, Africa, the Middle East, Asia, and
the Western Pacific2 (Figure 1), but not in Japan.13 The USA,
Europe, and Australia are also areas of low endemicity.
Hepatitis A tends to be endemic in developing countries with
poor sanitation, where most of the population becomes
exposed during childhood and is thus immune to symptomatic
infection. Nonetheless, HAV remains in these communities
because it is environmentally stable.2
With the exception of sporadic outbreaks, the incidence
of hepatitis A in the USA has decreased considerably in the
last few decades.8,14 This finding might suggest that its
importance is waning; however, the contrary is true, which
explains the recent Advisory Committee on Immunization
Practices’ (ACIP) recommendation for universal childhood
vaccination against hepatitis A.6 Low herd immunity means
that the adult population is nowmore likely to be susceptible
to infection, so the potential burden on society is higher.
HBV is transmitted by contact with contaminated body
fluids, primarily blood and serous fluid, but also semen andsaliva. Viral shedding can occur for 1—2 months before and
after the onset of symptoms. The four main routes of trans-
mission are perinatal, horizontal (close contact with an
infected individual), sexual, and parenteral (e.g., using a
contaminated hypodermic needle). HBV is highly endemic in
China, Southeast Asia, parts of Africa, the Pacific Basin (South
and Western Pacific Islands, excluding Australia, New Zeal-
and, and Japan), the Middle East (excluding Israel), the
interior Amazon River Basin, and certain parts of the Car-
ibbean (Haiti and the Dominican Republic). The USA, Western
Europe, and Australia are areas of low endemicity
(Figure 1).3,15
The incidence of HBV in the USA has fallen dramatically
during the last decade because of the design and implemen-
tation of a vaccination strategy intended to eliminate HBV
transmission. This approach includes routine screening of all
pregnant women for HBV infectivity, universal vaccination of
babies and all children <19 years of age, and targeted
immunization of adults in high-risk groups.8 Although HBV
6 J.S. Keystone, J.H. Hersheyappears to be in decline in younger age groups, high rates of
disease are still seen in adults, particularly individuals in
identified risk groups (e.g., illicit drug users and individuals
participating in high-risk sexual behavior).8
Who is at risk of acquiring HAV or HBV?
During 2003, the most commonly identified cause of HAV in
the USA was a food-related outbreak,2 but ingestion of HAV-
contaminated food or water is more likely to occur when
traveling abroad to areas where sanitary conditions are poor,
even when staying in a luxury hotel. Although the risk of HAV
infection for those traveling outside the USAvaries with living
conditions, length of stay, and the incidence of HAV infection
in the area visited, many cases of HAVoccur in those traveling
to developing countries with standard tourist itineraries,
accommodation, and food consumption behavior. HAV is
the third most common vaccine-preventable infection in
international travelers after enterotoxigenic Escherichia coli
infection and influenza. The risk associated with interna-
tional travel is not unique to US citizens. It has been reported
that one-third of all hepatitis A cases diagnosed in Switzer-
land during the last decade were acquired while the indivi-
dual was abroad.16
Although international travel per se has not been cited as
a suspected risk factor in the acquisition of HBV, the results of
several surveys suggest that travelers often engage in high-
risk behaviors when visiting endemic areas, such as recrea-
tional drug taking or casual, unprotected sex with locals.17—24
Frequently, these individuals are not adequately immunized
before departure.17,19,20,25 Other potential sources of HBVFigure 2 Trends in selected epidemiologic characteristics ainfection include cosmetic procedures such as tattooing or
body piercing, which are not uncommon among visitors to
destinations where HAV and HBV are endemic.26 Zuckerman
and Steffen (2000) surveyed more than 9000 travelers and
reported that 7—11% had been at high risk of HBV infection,
and 61—76% at moderate risk.25 The majority were not
vaccinated prior to travel. They also found that significantly
more travelers visiting hepatitis B endemic areas engaged in
high-risk activities than those travelers visiting non-endemic
regions.25 Nosocomial HBV infection is common in areas of
HBV endemicity because of the use of contaminated blood,
blood products, or non-sterile instruments.27 Therefore, an
unplanned medical or dental intervention can also be a risk
factor for HBV exposure.25 Correia and coworkers reported
their findings from a survey of 400 travelers from Canada
about high-risk activity while abroad.18 They noted a total of
77 occasions of potential exposure to blood and other body
fluids among 60 (15.0%) of the travelers, including unpro-
tected sex, receipt of acupuncture or a tattoo, medical
intervention, and sharing a razor. Furthermore, a survey of
784 US returned international travelers showed that 8%
of travelers sought medical attention while abroad and
17% of those who received medical care were administered
an injection.28 Reuse of injection equipment in the absence
of sterilization is a major risk factor for HBV exposure, and a
recent review of worldwide injection practices reported that
between 1.2% (Europe) and 75% (Southeast Asia) of injections
administered are done so using previously used injection
equipment without prior sterilization.29 Together, these stu-
dies illustrate why all travelers to areas of medium to high
HBV endemicity are at risk of HBV infection. The need formong patients with hepatitis A by year; USA 1998—2004.8
The underestimated risk of hepatitis A and hepatitis B 7medical intervention such as administration of intravenous
fluids for rehydration, injection of an anti-emetic for vomit-
ing, or localized surgery for an injury, cannot be predicted.
Even if vaccination advice is sought before travel, business
trips and last-minute holidays often mean that travel is
organized at short notice, leaving insufficient time to com-
plete the standard immunization schedule for HAV and HBV.
Airport surveys of travelers from Europe, South Africa, and
the USA revealed that approximately 50% planned their trip
to developing nations less than 4 weeks in advance, and few
sought travel-related healthcare advice before depar-
ture.17,19,20
HAV and HBV may be disseminated from travelers on their
return to areas of low endemicity, where most inhabitants
remain unprotected against these infections. In the USA in
2004, hepatitis A was most often spread through direct
personal contact (sexual or non-sexual).8 Two major domes-
tic risk factors for acquiring hepatitis A include engaging in
sexual activity with an infected person and injection drug
use. Outbreaks are also a source of infection and have been
reported in daycare facilities, where poor hygiene, such as
not washing hands after changing a diaper, could spread the
infection (Figure 2, Table 1).8 During 2004, sexual activity
and injection drug use were the two most frequently cited
high-risk activities that preceded new cases of hepatitis B in
the USA (Figure 3, Table 2).8 Because sexual transmission is a
significant factor in the epidemiology of both hepatitis A and
hepatitis B, prison inmates, particularly men who have sex
with men (MSM), and persons who attend sexually trans-
mitted infection (STI) clinics are at an increased risk of these
infections.6,30—33 The presence of one STI increases the like-
lihood that the same patient will have a second STI concur-
rently.34 Although activities likely to transmit HAV and HBV
(homosexual encounters and illicit drug use) are prohibited inTable 1 Epidemiologic characteristics of patients with hepatitis
Exposures during the 2—6 weeks
before illness onset
Age groups
<15 1
n N % n
Sexual or household contact
with hepatitis A patient
71 413 17.2
International travela 189 501 37.7 1
Male homosexual activityb — 11 —
Injection drug use 5 392 1.3 1
Child/employee in daycare center 65 488 13.3
Suspected food- or waterborne outbreak 102 416 24.5
Contact of daycare child/employee 41 449 9.1
Other contact with hepatitis A patients c 101 413 24.5
No risk factor identified 181 534 33.9 4
No risk factor data submitted — 642 —
Total — 1176 —
Note: The percentage of cases reporting a specific risk factor (n) was
information for that exposure. Multiple risk factors can be reported fo
a Of cases attributed to a region endemic for hepatitis A, 59% traveled
Africa, and 9% from the Middle East. The high proportion of cases asso
several US states that occurred among refugee populations recently re
b Among male cases, 5% were attributed to homosexual behavior.
c Examples of other contact include playmate, drug sharing contact,jails and prisons, they do still occur and have the potential to
lead to a considerable disease burden in these institu-
tions.30,32,33
Hepatitis A and hepatitis B vaccines
There is now a universal childhood vaccination policy in the
USA for hepatitis A.6 This policy was introduced over a decade
ago for hepatitis B.35 Most of the adult population has not
been immunized against either disease, so vaccination is also
recommended for those at increased risk of contracting HAV
and/or HBV through their occupation, travel, lifestyle, or
incarceration.6,11,32 Highly effective monovalent vaccines
against HAV and HBV are available. Hepatitis A vaccines were
introduced in the USA during 1995—1996 for individuals 2
years of age and are now licensed for use after 12 months of
age.2 A plasma-derived hepatitis B vaccine, produced from
the 22 nm HBsAg particles purified from the plasma of human
carriers, was licensed for use in the USA in 1981, but was not
well accepted. The vaccine was taken off the market in the
USA in 1992, due to unsupported fears of transmission of live
HBVand other blood borne pathogens. Recombinant vaccines
against hepatitis B were introduced in 1986 and 1989, and are
presently licensed for use from birth.3
In 2001, a combination vaccine against both hepatitis A
and hepatitis B was introduced in the USA (Twinrix1, Glax-
oSmithKline Biologicals, Rixensart, Belgium), which is
licensed for use in persons 18 years of age.36 Immunization
for adults consists of three doses given at 0, 1, and 6 months,
and Twinrix is as safe and effective as the monovalent
vaccines.37,38 Within the European Union, Twinrix can also
be administered according to an accelerated schedule in
which three doses are given within 21 days (at 0, 7, and
21 days), followed by a fourth dose after one year. ThisA by age; USA, 20048
5—39 40+ Total
N % n N % n N %
93 777 12.0 47 734 6.4 211 1924 11.0
38 909 15.2 68 853 8.0 395 2263 17.5
10 394 2.5 7 285 2.5 17 690 2.5
80 772 23.3 43 633 6.8 228 1797 12.7
65 887 7.3 23 812 2.8 153 2187 7.0
52 736 7.1 36 716 5.0 190 1868 10.2
58 764 7.6 23 711 3.2 122 1924 6.3
73 777 9.4 35 734 4.8 209 1924 10.9
97 1024 48.5 706 942 74.9 1384 2500 55.4
— 1056 — — 1373 — — 3071 —
— 2080 — — 2315 — — 5571 —
calculated based on the total number of cases (N) reporting any
r a single case.
from South/Central America, 28% from Asia/South Pacific, 4% from
ciated with travel from Asia/South Pacific reflects an outbreak in
located from a single refugee camp in Thailand.
or care provider.
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Figure 3 Trends in selected epidemiologic characteristics among patients with hepatitis B by year; USA 1998—2004.8
Table 2 Epidemiologic characteristics of patients with acute hepatitis B by age; USA, 20048
Exposures during the 6 weeks to
6 months before illness onset
Age groups
<45a 45+ Total
n N % n N % n N %
Injection drug use 301 1540 19.5 61 742 8.2 362 2282 15.9
Sexual contact with hepatitis B patient 122 1109 11.0 39 553 7.1 161 1662 9.7
Household contact of hepatitis B patient 25 1109 2.3 18 553 3.3 43 1662 2.6
Male homosexual activityb 119 843 14.1 27 358 7.5 146 1201 12.2
Medical employee with blood contact 4 1554 0.3 7 763 0.9 11 2317 0.5
Hemodialysis 5 1287 0.4 5 597 0.8 10 1884 0.5
More than one sex partner 402 1098 36.6 130 518 25.1 532 1616 32.9
Heterosexual 348 1002 34.7 118 497 23.7 466 1499 31.1
Male homosexual or bisexual 54 96 56.3 12 21 57.1 66 117 56.4
Blood transfusion 2 1573 0.1 13 752 1.7 15 2325 0.6
Surgery 97 1460 6.6 85 717 11.9 182 2177 8.4
Percutaneous injury (e.g. needlestick) 50 1340 3.7 25 665 3.8 75 2005 3.7
No risk factor identified 934 1803 51.8 513 835 61.4 1447 2638 54.9
No risk factor data submitted — 2279 — — 1187 — — 3466 —
Total — 4082 — — 2022 — — 6104 —
Note: The percentage of cases reporting a specific risk factor (n) was calculated based on the total number of cases (N) reporting any
information for that exposure. Multiple risk factors can be reported for a single case.
a 104 (2%) of all cases were <19 years of age.
b When calculated for male cases only, 205 homosexual behavior.
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Table 3 Primary and booster course: seroconversion rates and GMC values (mIU/ml) of anti-HAV antibody concentrations.
(Reprinted with permission from Nothdurft et al.45)
Time Group 1. Combined vaccine Group 2. Monovalent vaccine
N S+ (%) (95% CI) GMC (95% CI) N S+ (%) (95% CI) GMC (95% CI) Differencea (95% CI)
M1 211 100 (98.3—100) 845 (746—957) 192 99.0 (96.3—99.9) 512 (441—595) 1.04 (0.66—2.74)
M2 206 99.5 (97.3—100) 780 (681—892) 189 98.9 (96.2—99.9) 286 (248—331) 0.57 (1.44—2.58)
M3 206 100 (98.2—100) 628 (554—712) 185 97.8 (94.6—99.4) 219 (187—256) 2.16 (0.21—4.53)
M12 183 96.2 (92.3—98.5) 374 (315—442) 179 95.0 (90.7—97.7) 170 (143—202) 1.20 (3.33—5.73)
M13 183 100 (98.0—100) 9571 (8316—11 017) 179 100 (98.0—100) 5205 (4430—6116) 0.00 (0.28—0.28)
Vaccines administered on days 0, 7, and 21 with a fourth vaccine dose at month 12. GMC, geometric mean concentration; M, month; N, total
number of subjects; S+, seroconversion rate; group 1, combined hepatitis A and hepatitis B vaccination; group 2, separate hepatitis A and
hepatitis B vaccinations; 95% CI, exact 95% confidence interval.
a Between group difference in seroconversion rate.accelerated schedule has demonstrated suitable immuno-
genicity for the last-minute traveler.39 This schedule has
recently been approved by the Food and Drug Administration
(FDA) in the USA.
Vaccination strategies to prevent hepatitis A
and hepatitis B disease
Earlier this year, ACIP published a recommendation for
universal vaccination of infants 1 year of age against
hepatitis A, and vaccination of non-immune adults who
are at an increased risk of HAV infection (including trave-
lers, MSM, and injection drugs users).6 ACIP also recom-
mended that ‘catch-up’ vaccination of unvaccinated
children 2—18 years of age should be considered.6 Universal
childhood vaccination against HBV was recommended in
1991,40 and to protect the mostly non-immune adult popu-
lation, it is recommended that all adults at high risk of HBV
are also vaccinated. It was recently stated that all indivi-
duals traveling to areas of high endemicity should now be
vaccinated against hepatitis A, regardless of their duration
of stay.6 Until recently, only travelers planning high-risk
behavior during an extended stay in HBV endemic areas
were advised to seek vaccination before their trip, but this
policy is now being challenged. Published data have
suggested a potential risk of HBV infection in short stay
travelers as well,41 particularly because behavior likely to
expose an individual to infection while abroad (such as theTable 4 Primary and booster course: seroconversion rates and GM
permission from Nothdurft et al.45)
Time Group 1. Combined vaccine Group 2.
N S+ (%) (95% CI) GMC (95% CI) N S+ (
M1 211 82.0 (76.1—86.9) 65 (51—82) 192 83
M2 206 85.0 (79.3—89.5) 53 (44—64) 189 84
M3 206 95.2 (91.3—97.7) 183 (150—223) 185 90
M12 183 94.0 (89.5—97.0) 209 (168—230) 179 91
M13 183 100 (98.0—100) 26 002 (20 271—33 354) 179 100
Vaccines administered on days 0, 7, and 21 with a fourth vaccine dose at
number of subjects; S+, seroconversion rate; group 1, combined hepati
hepatitis B vaccinations; 95% CI, exact 95% confidence interval.
a Between group difference in seroconversion rate.need for medical or dental treatment) is not always planned
before departure.25 A policy of universal vaccination
against hepatitis A and hepatitis B in travelers to endemic
areas may thus be prudent.
Illicit drug use is another risk factor that necessitates
immunization against hepatitis A and hepatitis B, but many
community-based users of illicit drugs do not have contact
with healthcare systems, making vaccination difficult. Prison
may provide an opportunity to vaccinate these individuals.42
Despite CDC recommendations that all individuals with a
history of high-risk behavior be immunized,32,43 many prisons
do not have HAV and HBV vaccination programs in place. A
recent study suggested that it may be cost-effective to
administer vaccines against hepatitis A and hepatitis B at
the same time in this setting, rather than just immunizing
against hepatitis B.44
Who would benefit from an accelerated
schedule?
People traveling to HAVand HBVendemic areas can be at risk
of exposure to both HAVand HBV, even if they do not plan to
participate in high-risk behavior while there. As many ‘last-
minute’ travelers do not prepare for travel until shortly
before departure, a standard 6-month vaccination schedule
for hepatitis A and hepatitis B vaccines cannot be com-
pleted, resulting in suboptimal protection. Administering
a combination hepatitis A and hepatitis B vaccine on anC values (mIU/ml) of anti-HBs concentrations. (Reprinted with
Monovalent vaccine
%) (95% CI) GMC (95% CI) Differencea (95% CI)
.9 (77.9—88.8) 98 (75—129) 1.86 (9.49—5.76)
.9 (78.9—89.6) 58 (46—72) 0.13 (7.20—7.47)
.8 (85.6—94.5) 131 (105—163) 4.38 (1.01—9.78)
.6 (86.6—95.2) 106 (84—133) 2.37 (3.25—7.99)
(98.0—100) 29 196 (21 606—39 453) 0.00 (0.28—0.28)
month 12.GMC, geometric mean concentration; M, month; N, total
tis A and hepatitis B vaccination; group 2, separate hepatitis A and
10 J.S. Keystone, J.H. Hersheyaccelerated schedule provides rapid protection (Tables 3
and 4) and so is likely to benefit last-minute trave-
lers.26,39,45,46 The accelerated schedule may also encourage
the recipient to complete the vaccination course.47 Studies
have demonstrated that administering Twinrix on an accel-
erated schedule confers equivalent protection compared to
the administration of separate vaccines given on an equiva-
lent or alternate schedule.39,46 At month 13, following
administration of the 12-month dose, a 100% HAV serocon-
version rate in groups receiving Twinrix has been
reported.39,46 Reported HBV seroprotection rates in the
samegroupswere in the 96.4—100% range.39,46 Neither study
reported differences in HAV seroconversion rates, or HBV
seroprotection rates, between the two vaccine groups.
Correctional facilities, where HAV and HBV are trans-
mitted through participation in high-risk behavior, have a
greater prevalence of both infections than the general popu-
lation.34 As incarceration often occurs at short notice, immu-
nization using an accelerated schedule may benefit this
vulnerable group. Also, inmates may be moved between
facilities with little prior warning or serve sentences for less
than six months. Administering vaccines according to an
accelerated schedule could result in increased adherence
to, and completion of, the vaccination schedule. Similarly,
illicit drug users do not usually have long-term contact with
healthcare systems, and appropriate opportunities for vac-
cination may occur while drug users are residing in rehabi-
litation facilities. Again, vaccine administration according to
an accelerated schedule could result in an increase in sche-
dule completion rates.
Conclusions
Routine immunization against hepatitis A and hepatitis B of
all travelers to endemic areas, regardless of their duration of
stay, and of prison inmates who engage in behaviors that
enhance their risk of exposure, represents a consensus on the
optimal vaccination strategy to decrease the burden and
prevent the spread of both diseases. The epidemiologic data
suggest that the incidence of HAV is falling in the USA, which
will likely result in fewer people with naturally acquired
immunity against hepatitis A. Acute infections with HBV
are also declining, but certain high-risk groups still experi-
ence a high rate of HBV infection. It is estimated that 5000—
8000 persons become chronically infectedwith HBVeach year
in addition to the 1—1.25 million individuals already chroni-
cally infected.3 Given the significant burden that these dis-
eases place on patients, healthcare systems, and the
economy, and the potential for considerable future hepatitis
related morbidity and mortality in the current adult popula-
tion, it would seem that more widespread vaccination of at-
risk groups is needed until we begin to reap the benefits of
universal childhood vaccination.
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